Chest
EditorialsCOPD, Inflammation and Its Modulation by Phosphodiesterase 4 Inhibitors: Time to Look Beyond the FEV1
References (9)
- et al.
Immunosuppressive and anti-inflammatory effects of cyclic AMP phosphodiesterase (PDE) type 4 inhibitors
Immunopharmacology
(2000) Cyclic nucleotide phosphodiesterases
J Allergy Clin Immunol
(2001)- et al.
Roflumilast: an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomized controlled trial
Lancet
(2005) - et al.
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Lancet
(1997)
Cited by (9)
Novel bronchodilators for the treatment of chronic obstructive pulmonary disease
2011, Trends in Pharmacological SciencesCitation Excerpt :These small changes in FEV1 clearly indicate that PDE4 inhibitors are not true bronchodilators. It is possible, as suggested by Celli [43], that PDE4 inhibitors could reach the distal airways because of their systemic distribution, where decreasing inflammation around the small airways could result in more important changes in resting lung volumes than in absolute FEV1. In any case, it has been demonstrated that PDE4 inhibitors can relax inherent tone in isolated human bronchial muscle [44] and, moreover, that the PDE4D variant 5 is the key physiological regulator of β2-AR-induced cAMP turnover within human airway smooth muscle [45].
Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients
2013, International Journal of COPDPharmacology and therapeutics of bronchodilators
2012, Pharmacological ReviewsEmerging drugs for chronic obstructive pulmonary disease
2012, Expert Opinion on Emerging DrugsAnti-inflammatory properties of Septilin in lipopolysaccharide activated monocytes and macrophage
2011, Immunopharmacology and Immunotoxicology
Reproduction of this article is prohibited without written permission from the American College of Chest Physicians (www.chestjournal.org/misc/reprints.shtml).